Inactive Instrument

Opko Health Share Price Nasdaq

Equities

Healthcare Facilities & Services

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 72Cr 5.97TCr Sales 2025 * 75Cr 6.3TCr Capitalization 88Cr 7.33TCr
Net income 2024 * -26Cr -2.21TCr Net income 2025 * -23Cr -1.91TCr EV / Sales 2024 * 1.23 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
-3.38 x
P/E ratio 2025 *
-3.96 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 45.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 87 27/07/27
Director of Finance/CFO 46 01/07/01
President 72 09/22/09
Members of the board TitleAgeSince
Chief Executive Officer 87 27/07/27
Director/Board Member 77 18/20/18
Director/Board Member 68 01/08/01
More insiders
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Related indices
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW